In weighing which indications to pursue first, biopharmas must consider a therapeutic candidate’s potential value to patients as well as the need to fund future innovation.
When done well, indication prioritization projects involve reliable bioinformatics analyses and comprehensive market assessment. In this webinar, Clarivate’s bioinformatics and market assessment experts share insights to answer: